ProPhase Labs Files 8-K

TL;DR

ProPhase Labs filed an 8-K, check for updates.

AI Summary

ProPhase Labs, Inc. filed an 8-K on November 7, 2024, to report other events and financial statements. The filing does not contain specific details about the nature of these events or financial figures within the provided text.

Why It Matters

This filing indicates ProPhase Labs is making a regulatory submission to the SEC, which could contain important updates for investors.

Risk Assessment

Risk Level: low — The filing is a standard procedural document without immediate negative or positive financial implications disclosed in the provided text.

Key Players & Entities

• ProPhase Labs, Inc. (company) — Registrant
• November 7, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 000-21617 (filing_id) — SEC File Number
• 23-2577138 (tax_id) — I.R.S. Employer Identification No.
• 711 Stewart Avenue, Suite 200 Garden City, New York 11530 (address) — Address of principal executive offices
• (215) 345-0919 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.0005 — ch Registered Common Stock, par value $0.0005 PRPH Nasdaq Capital Market Indic
• $500,000 — ndividual investor for cash proceeds of $500,000 (the "Term Note"). The Term Note has an
• $6,250 — only monthly payments in the amount of $6,250 with a $506,250 balloon payment at end
• $506,250 b — payments in the amount of $6,250 with a $506,250 balloon payment at end of term. There are
• $17,500 — o the Company on August 2, 2024, net of $17,500 origination fee. The Company also incur
• $17,500 b — gination fee. The Company also incurred $17,500 brokerage fee. The Third Future Receipts
• $21,094 — greement requires 32 weekly payments of $21,094 for a total repayment of $675,000 over
• $675,000 — nts of $21,094 for a total repayment of $675,000 over the term of the agreement. Neith
• $1.5 m — ers. The purchase price was approximate $1.5 million, which was paid to the Company on
• $42,000 — to the Company on June 28, 2024, net of $42,000 origination fee. The Company also incur
• $22,000 b — gination fee. The Company also incurred $22,000 brokerage fee which was paid subsequently
• $60,718 — greement required 32 weekly payments of $60,718 for a total repayment of approximately
• $1.9 million — for a total repayment of approximately $1.9 million over the term of the agreement. During
• $9,000 — d June 30, 2024, the Company recognized $9,000 interest expense from the amortization
• $1.4 m — Future Receipts Financing Agreement was $1.4 million, net of debt discount of $548,000

Filing Documents

• form8-k.htm (8-K) — 64KB
• ex99-1.htm (EX-99.1) — 16KB
• image_001.jpg (GRAPHIC) — 21KB
• 0001493152-24-044017.txt ( ) — 293KB
• prph-20241107.xsd (EX-101.SCH) — 3KB
• prph-20241107_lab.xml (EX-101.LAB) — 33KB
• prph-20241107_pre.xml (EX-101.PRE) — 24KB
• form8-k_htm.xml (XML) — 4KB

Risk Factors

Risk Factors FDA's finalized regulations on laboratory-developed tests may impact our operations adversely, and we may not be able to comply with the requirements. We market our genetic tests as laboratory-developed tests ("LDT"), and plan to also initially market our BE-Smart Esophageal Pre-Cancer as an LDT. Until recently, the FDA has exercised enforcement discretion on LDTs that are marketed in the United States, provided that the LDTs can meet certain conditions that the FDA has outlined. However, on May 6, 2024, the FDA issued a final rule aimed at helping to ensure the safety and effectiveness of laboratory developed tests (LDTs). The rule amends the FDA's regulations to make explicit that in vitro diagnostic products ("IVD") are medical devices under the Federal Food, Drug, and Cosmetic Act (FD&C Act) including when the manufacturer of the IVD is a laboratory. Along with this amendment, the FDA is finalizing a policy under which the FDA will provide greater oversight of IVDs offered as LDTs through a phaseout of its general enforcement discretion approach for LDTs over the course of four years, as well as targeted enforcement discretion policies for certain categories of IVDs manufactured by laboratories. As a result of the final regulations, premarket review, clearance, or approvals may be required by FDA for the products that we are currently marketing or plan to market as LDTs. Our business and operations may be adversely affected because we may be required to cease sales of such products and be required to expend significant resources into collecting data from clinical trials, ensuring compliance with the applicable requirements for medical devices, and preparing and submitting premarket applications for the FDA's review. We may not be able to complete the required clinical trials to enable marketing of our tests due to resource constraints, or we may not be able to complete them in a timely manner. We also may not be able to comply with the associate

View Full Filing

View this 8-K filing on SEC EDGAR